- Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy
- Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures
- Supernus Announces First Quarter 2024 Financial Results
- Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree Story
- Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
- Supernus Provides Regulatory Update for SPN-830
- Supernus to Participate in Two Upcoming Investor Conferences
- Supernus to Participate in the TD Cowen 44th Annual Healthcare Conference
- Supernus Announces Fourth Quarter and Full Year 2023 Financial Results
- Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 27, 2024
More ▼
Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | 21.99 |
---|---|
High | 21.99 |
Low | 21.99 |
Bid | 21.87 |
Offer | 22.08 |
Previous close | 21.99 |
Average volume | -- |
---|---|
Shares outstanding | 54.97m |
Free float | 52.21m |
P/E (TTM) | -- |
Market cap | 1.53bn USD |
EPS (TTM) | -0.2843 USD |
Data delayed at least 15 minutes, as of Dec 29 2020.
More ▼